POLARIS program, launched in 2024 to evaluate ETX101 for SCN1A+ Dravet syndrome, is ongoing. Expect to complete dosing and share preliminary safety and efficacy data in 2H25. ETX201 gene therapy ...
Designation based on preliminary clinical evidence indicating the potential for ETX101 to address unmet medical needs associated with SCN1A+ Dravet syndrome Completion of enrollment in POLARIS ...
Encoded Therapeutics is joining the ranks of biotechs pummeled by the whiplash of a difficult biotech market, laying off "close to 10%" of its team, according to Chief Business Officer David McNinch.
GW Pharma’s Epidiolex made history in 2018 when the cannabis-based treatment scored an FDA nod for Dravet syndrome, a genetic disorder marked by intractable seizures. But children with Dravet face ...
Encoded Therapeutics, Inc. ("Encoded"), a clinical-stage biotechnology company developing precision genetic medicines for severe neurological disorders, today announced that the U.S. Food and Drug ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics today announced the upcoming presentation of initial data from the ENVISION prospective natural history study of children with SCN1A+ ...
AAV9-based Angelman Syndrome candidate, ETX201, demonstrates safety and target engagement in non-human primates (NHPs), with unsilencing of UBE3A across disease-relevant brain regions Multiple ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a clinical-stage biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results